Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

PHGE
BiomX Inc.
stock NYSEAMERICAN

At Close
Jun 6, 2025 3:59:30 PM EDT
0.4593USD-6.263%(-0.0307)684,469
0.00Bid   0.00Ask   0.0000Spread
Pre-market
Jun 6, 2025 8:07:30 AM EDT
0.5150USD+5.102%(+0.0250)120
After-hours
Jun 3, 2025 4:31:30 PM EDT
0.5010USD0.000%(0.0000)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 4, 2022
07:13AM EST  BiomX Announces Therapeutics Development Award Of Up To $5M From The Cystic Fibrosis Foundation   Benzinga
07:00AM EST  BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation   Business Wire
Nov 17, 2021
08:00AM EST  Jefferies London Healthcare Conference on November 18 - 19, 2021   GlobeNewswire Inc
Nov 16, 2021
09:25AM EST  Chardan Capital Maintains Buy on BiomX, Lowers Price Target to $13   Benzinga
Nov 15, 2021
11:07AM EST  Earnings Scheduled For November 15, 2021   Benzinga
10:48AM EST  BiomX Q3 EPS $(0.37) Misses $(0.25) Estimate   Benzinga
06:14AM EST  BiomX Q3 Loss Per Share $0.37 Vs Loss $0.38 Last Year   RTTNews
06:00AM EST  Announces Strategic FocusonCystic Fibrosis and Atopic Dermatitis ProgramsBased on Potential Proof-of-Concept Clinical Data Readouts in 2022   GlobeNewswire Inc
Nov 9, 2021
08:00AM EST  BiomX to Host Third Quarter 2021 Financial Results Conference Call   GlobeNewswire Inc
Oct 19, 2021
08:45AM EDT  Chardan Capital Maintains Buy on BiomX, Lowers Price Target to $16   Benzinga
Oct 18, 2021
12:56PM EDT  HC Wainwright & Co. Maintains Buy on BiomX, Lowers Price Target to $10   Benzinga
07:20AM EDT  BiomX Inc. Says 12-Week Study Of BX001 Meets Safety And Tolerability Endpoints   RTTNews
07:08AM EDT  BiomX Reports Results Of Phase 2 Cosmetic Acne Study Showed Statistically Significant Improvement From Baseline Observed In Appearance Of Acne-prone Skin But No Meaningful Difference Demonstrated Relative To Vehicle   Benzinga
07:00AM EDT  12-Week Study of BX001 Meets Safety and Tolerability Endpoints   GlobeNewswire Inc
Oct 13, 2021
01:38PM EDT  BiomX Enters Agreement Granting Maruho Co. A right Of First Offer To License BiomX's Atopic Dermatitis Product Candidate BX005; Maruho Will Also Enter Binding Agreement For $3M Equity Investment In BiomX   Benzinga
01:38PM EDT  The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal   Benzinga
07:00AM EDT  BiomX Announces Agreement with Maruho Co., Ltd. for Atopic   GlobeNewswire Inc
Sep 2, 2021
04:05PM EDT  BiomX Inc. (NYSE American: PHGE) (BiomX or the Company), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced Jonathan Solomon, Chief Executive Officer, will be presenting at three upcoming virtual investor events in September.   GlobeNewswire Inc
Aug 16, 2021
06:34AM EDT  BiomX Q2 EPS $(0.30) Beats $(0.37) Estimate   Benzinga
06:30AM EDT  Up to $45 Million Secured from Recent Capital Raises Extends Cash Runway to at Least Mid-2023   GlobeNewswire Inc
04:04AM EDT  Earnings Scheduled For August 16, 2021   Benzinga
Aug 12, 2021
08:00AM EDT  BiomX to Host Second Quarter 2021 Financial Results Conference   GlobeNewswire Inc
Jul 26, 2021
08:20AM EDT  BiomX Inc. Announces $15M Registered Direct Offering   Benzinga
08:14AM EDT  BiomX Inc. Announces $15 Million Registered Direct Offering   GlobeNewswire Inc
Jun 14, 2021
06:38AM EDT  BiomX Presents Preclinical Results With BX005 In Atopic Dermatitis   RTTNews
06:30AM EDT  BiomX Presents Preclinical Results With BX005 for Atopic Dermatitis at the Revolutionizing Atopic Dermatitis 2021 Virtual Conference and the International Conference on Phage Therapy and Bacteriophages   Benzinga
Jun 9, 2021
06:35AM EDT  BiomX To Present Preclinical Results With BX004 In Cystic Fibrosis At 44th European Cystic Fibrosis Conference Jun. 9-11   Benzinga
06:30AM EDT  BiomX to Present Preclinical Results with BX004 in Cystic Fibrosis at the 44th European Cystic Fibrosis Conference   Business Wire
May 24, 2021
06:37AM EDT  BiomX Q1 Loss Per Share $0.35 Vs Loss $0.26 Last Year   RTTNews
06:30AM EDT  BiomX Q1 EPS $(0.35) Down From $(0.26) YoY   Benzinga
06:30AM EDT  BiomX Reports First Quarter 2021 Financial Results and Provides Business Updates   Business Wire
04:00AM EDT  Earnings Scheduled For May 24, 2021   Benzinga
May 18, 2021
08:00AM EDT  BiomX To Host Key Opinion Leader Event on BX003 for the Treatment   GlobeNewswire Inc
06:30AM EDT  BiomX to Host First Quarter 2021 Financial Results Conference Call and Webcast on May 24, 2021   Business Wire
Apr 20, 2021
07:00AM EDT  BiomX to Present at Upcoming April Investor Events   Business Wire
Apr 15, 2021
10:03AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 15, 2021   Benzinga
07:10AM EDT  Ladenburg Thalmann Initiates Coverage On BiomX with Buy Rating, Announces Price Target of $25   Benzinga
Mar 31, 2021
07:41AM EDT  The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO   Benzinga
06:38AM EDT  BiomX Q4 Net Loss $9.1 Mln Vs Loss $9.3 Mln Last Year   RTTNews
06:30AM EDT  BiomX Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update   Business Wire
04:26AM EDT  Earnings Scheduled For March 31, 2021   Benzinga
Mar 27, 2021
01:01PM EDT  The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week   Benzinga
Mar 24, 2021
06:30AM EDT  BiomX to Report Fourth Quarter and Full Year 2020 Financial Results on March 31, 2021   Business Wire
Mar 2, 2021
07:20AM EST  BiomX Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin   Benzinga
07:09AM EST  BiomX Says First Subject Dosed In Phase 2 Cosmetic Clinical Study Of BX001   RTTNews
07:00AM EST  BiomX Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin   Business Wire
Mar 1, 2021
07:00AM EST  BiomX to Present at Upcoming March Investor Conferences   Business Wire
Feb 2, 2021
11:16AM EST  BiomX's BX002 Shows Promising Action In Early-Stage Study In Healthy Volunteers   Benzinga
06:42AM EST  BiomX Announces Results Of Phase 1a Pharmacokinetic Study For Inflammatory Bowel Disease/Primary Sclerosing Cholangitis Evaluating Delivery Of Oral BX002 Phage Therapy; Says BX002 Demonstrated Safety And Tolerability   Benzinga
06:30AM EST  BiomX Announces Positive Results of a Phase 1a Pharmacokinetic Study for Inflammatory Bowel Disease/Primary Sclerosing Cholangitis (IBD/PSC) Evaluating Delivery of Oral BX002 Phage Therapy   Business Wire
Jan 4, 2021
06:30AM EST  BiomX to Present at Upcoming January Investor Conferences   Business Wire
Dec 9, 2020
04:33PM EST  BiomX Announces Presentation Of Preclinical Results Of Analysis Of Patient Samples And Engineering Of Phage For Therapeutic Applications In Colorectal Cancer   Benzinga
04:33PM EST  BiomX Offers Preclinical Results Of Analysis Of Patients Samples, Engineering Of Phage For Therapeutic Applications In Colorectal Cancer: 'Specific targetable bacteria observed in over 80 percent of patient colorectal tumor samples'   Benzinga
04:30PM EST  BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer   Business Wire
Dec 7, 2020
06:59AM EST  HC Wainwright & Co. Initiates Coverage On BiomX with Buy Rating, Announces Price Target of $20   Benzinga
Nov 16, 2020
06:36AM EST  BiomX Presents Preclinical Results of Phage Targeting Klebsiella pneumoniae for Primary Sclerosing Cholangitis and Inflammatory Bowel Disease   Benzinga
06:35AM EST  BiomX Presents Preclinical Results Of Phage Targeting Klebsiella Pneumoniae For Primary Sclerosing Cholangitis And IBD   RTTNews
06:30AM EST  BiomX Presents Preclinical Results of Phage Targeting Klebsiella pneumoniae for Primary Sclerosing Cholangitis and Inflammatory Bowel Disease   Business Wire
Nov 12, 2020
06:44AM EST  BiomX Q3 Net Loss $8.8 Mln Vs $4.3 Mln Last Year   RTTNews
06:34AM EST  BiomX Inc Reports Q3 Net Loss of $8.8M Compared To A Net Loss of $4.3M In The Same Period Last Year   Benzinga
06:30AM EST  BiomX Reports Third Quarter 2020 Financial Results and Announces Expanded Portfolio of Phage Therapy Candidates   Business Wire
04:18AM EST  Earnings Scheduled For November 12, 2020   Benzinga
Nov 10, 2020
04:30PM EST  BiomX to Present at Upcoming November Investor Conferences   Business Wire
Nov 5, 2020
06:30AM EST  BiomX to Report Third Quarter 2020 Financial Results on Nov. 12, 2020   Business Wire
Nov 4, 2020
06:36AM EST  BiomX Announces Dosing Of First Subject In Phase 1a Study Of BX002 Phage Therapy For Inflammatory Bowel Disease   Benzinga
Oct 21, 2020
06:37AM EDT  BiomX Presents Preclinical Data On Phage Targeting Multidrug Resistant Klebsiella Pneumoniae Bacteria   RTTNews
06:34AM EDT  BiomX Highlights Presentation Of Preclinical Data From Its Phage Panel At Infectious Disease Society of America IDWeek Conference 2020   Benzinga
06:30AM EDT  BiomX Presents Preclinical Data on Phage Targeting Multidrug Resistant Klebsiella pneumoniae Bacteria at the Infectious Disease Society of America (IDSA) IDWeek Conference 2020   Business Wire
Oct 5, 2020
06:38AM EDT  BiomX Appoints Paul Sekhri And Alan Moses To Board   RTTNews
06:30AM EDT  BiomX Appoints Paul Sekhri and Alan Moses, M.D., to Board of Directors   Business Wire
Sep 10, 2020
04:30PM EDT  BiomX to Present at Upcoming September Investor Conferences   Business Wire
Sep 2, 2020
06:38AM EDT  BiomX Enters Collaboration With Boehringer Ingelheim To Utilize XMarker Microbiome-based Biomarker Discovery Platform   RTTNews
06:31AM EDT  BiomX Enters Collaboration With Boehringer Ingelheim With Goal Of 'Discovering Microbiome-Based Biomarkers for Inflammatory Bowel Disease'   Benzinga
06:30AM EDT  BiomX Enters Collaboration with Boehringer Ingelheim with the Goal of Discovering Microbiome-Based Biomarkers for Inflammatory Bowel Disease   Business Wire
Aug 13, 2020
06:34AM EDT  BiomX Q2 Net Loss $6.2 Mln Vs Loss $3.8 Mln Last Year   RTTNews
06:31AM EDT  BiomX Q2 Net Loss $6.2M vs Loss $3.8M In Same Qtr. Last Year   Benzinga
06:30AM EDT  BiomX Reports Second Quarter 2020 Financial Results and Provides Business Update   Business Wire
04:03AM EDT  Earnings Scheduled For August 13, 2020   Benzinga
Aug 6, 2020
07:00AM EDT  BiomX to Report Second Quarter 2020 Financial Results on Aug. 13, 2020   Business Wire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC